therapeutics glp 1 activate reviews Frontiers Innovative Diabetes Therapies and Impact

doi: 10.1016/j.biopha.2018.08.088 18 MeierJJ

Multivariate analysis of fasting glucose showed that fasting glucose was lower in the placebo arm at 12 months (2.2 mmol/L 95%CI: 0.4, 4.1, p = 0.027) but not at 6 months (1.4 mmol/L, 95%CI 1.1, 3.9, p = 0.24) (Supplementary Tables 10.1 and 10.2)

GLP-1 exerts its biological effects by binding to a specific receptor (GLP-1R), which is expressed in different types of peripheral tissues and in the central nervous system [12]

, Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies, PLoS Genet, vol

Seaquist ER